HOME   SITE MAP   CONTACT US

SCYNEXIS, Inc. is a premier drug discovery and development company headquartered in Research Triangle Park, North Carolina. Its scientists have extensive experience in the life sciences industry having, together and individually, been involved in the discovery of innovative medicines over a broad range of therapy areas.

In the discovery phase SCYNEXIS offers its services primarily in the form of integrated research teams consisting of medicinal chemists, biologists, computational chemists, biochemists, analytical chemists and bioanalytical scientists to work on a collaborative basis with our customers on projects from hit to candidate selection. SCYNEXIS project leaders of these multi-disciplinary teams are knowledgeable scientists with years of industry experience. They coordinate and communicate key activities and drive resources to achieve success. SCYNEXIS research teams use powerful, proprietary technologies such as the HEOS® Software Suite, MEDCHEM-FACTORY® and KIT™ Kinase Inhibitor Technology to deliver maximum results to our customers.

Development phase services such as process chemistry and cGMP synthesis are available on a fee for service project basis. SCYNEXIS has tailored its development teams to be especially effective in moving projects from discovery to the clinic. By linking good science with regulatory compliance, SCYNEXIS ensures projects are completed to meet both a client’s expectations and current GMP guidelines.

SCYNEXIS has expanded its business model by building a proprietary pipeline that will be developed internally to proof-of-concept. The Company has taken a deliberate, strategic approach to expanding the business by choosing to focus first in an exciting new area—cyclophilin inhibition. The Company’s first candidate, SCY-635, is currently being studied in patients chronically infected with hepatitis C virus (HCV)—a disease for which there is a significant unmet need and which has the keen interest of the biopharmaceutical community. In addition, SCYNEXIS’s scientists are excited about the broader indications for cyclophilin inhibitors for the treatment of other infectious and inflammatory diseases. The Company expects to move at least one more candidate into the clinic in 2009. At the same time SCYNEXIS remains as committed as ever to delivering outstanding value to our fee for service and shared risk project customers.